The FDA continues to face challenges in its oversight of drug manufacturing plants overseas due to disruptions related to the COVID-19 pandemic and staff vacancies, according to a report from the U.S. Government Accountability Office published Tuesday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,